Aulos Bioscience aims to revolutionize cancer patient care through the development of pioneering Interleukin-2 therapeutics for the treatment of solid tumor cancers. Interleukin-2 or IL-2 is often described as a “double-edged sword” because of its ability both to suppress and activate the immune system. For cancer patients, increased levels of IL-2 correlate with improved survival. […]

Code Bio is using its novel targeted non-viral delivery platform to develop genetic medicines for serious and life-threatening diseases such as Type 1 Diabetes and Duchenne Muscular Dystrophy. Code Bio leverages its proprietary, novel, multivalent, synthetic DNA delivery platform, 3DNA, which has been engineered to overcome many of the challenges inherent with delivery of genetic […]

Muna Therapeutics aims to preserve brain function and enhance resilience to neurodegenerative diseases.  The company engages in the discovery and development of novel therapies that slow or stop devastating neurodegenerative diseases including Alzheimer’s, Frontotemporal Dementia, and Parkinson’s. These disorders impact memory, movement, language, behavior, and personality resulting in disability and death of millions of patients. […]